about
Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy.96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance.Inconsistent condom use among HIV-positive women in the "Treatment as Prevention Era": data from the Italian DIDI study.Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort.Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia.Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllersDiscrepancies between physician's perception of depression in HIV patients and self-reported CES-D-20 assessment: the DHIVA studyItalian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy.Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications.Italian consensus statement on paediatric HIV infection.Impact of pre-therapy viral load on virological response to modern first-line HAART.Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients.Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.Granulocytic Myeloid-Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level.Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study.Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.An anal cancer screening program for MSM in Italy: Prevalence of multiple HPV types and vaccine-targeted infections.Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1.HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.Bone marrow CD34+ progenitor cells may harbour HIV-DNA even in successfully treated patients.Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start.Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.Early ART in primary HIV infection may also preserve lymphopoiesis capability in circulating haematopoietic progenitor cells: a case report.Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy.Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study.Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection.Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era.Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy.The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy.Circulating levels and ex vivo production of beta-chemokines, interferon gamma, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: the effect of protease inhibitor therapy.Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis.Induced first abortion rates before and after HIV diagnosis: results of an Italian self-administered questionnaire survey carried out in 585 women living with HIV.Primary central nervous system lymphoma and brain biopsy in AIDS.
P50
Q30710478-BFC3FA33-FA51-4F01-80CF-86D1585B8AF3Q34041795-4AD6A4D9-62E4-4ADC-9BA2-8EF6FE75D7B2Q34341541-3072103C-8A71-454C-AE8A-305862B1E5D4Q34740696-D7D4EFF3-64A4-47B6-93EC-096DAB5FD972Q35019858-9657C650-2883-4F15-98D4-85CD993925F6Q35108221-5AC4FEF9-2F46-456D-9602-9B89DE5141DEQ35968753-3EA7B0EF-E273-4369-A929-41ACED71162DQ36102240-46A4C9A4-A7AA-48AD-A235-86FF81718795Q36336077-3D9B00E0-30C5-4B41-8A5E-9D90E56081D4Q36519123-96B0B373-FC3B-4A3F-8CC7-946896C56F42Q37500009-7816DDC4-705F-4440-A282-2CA2CB83275FQ37546217-1B2EE344-5543-4D2B-8AF3-01DC75CA538EQ37761853-AE9995B3-72EC-4B13-AB0F-D09887299D4BQ38427973-C88D2D8F-D5D8-4B8D-9FD7-FF90AA326379Q38468340-832337DB-780A-44CC-9D69-BB82F6F314CEQ39221388-B605624E-F5CA-484A-B54D-2B0A9A10BD2AQ39284140-6E1740DB-EB23-4F86-8F9E-C41EDDF134E6Q40382829-D0EC62FC-DE27-48BC-9467-7DE508BF8B1CQ40503712-6BC3A81F-660A-4F06-852D-D6A4A31EBD9EQ40583081-4FB86E02-EB83-4F04-9522-B9131FD84F51Q40616829-9B5A85AE-9D20-4083-B64A-482CB35125CCQ40986411-911B064B-B894-412C-AB91-C9DCB331C67AQ40998601-B0599BD0-CBB3-4C69-B700-C54B6D43CD5CQ41465991-704B8F41-459F-44FC-99D8-492F9D3CF688Q41498531-7222766A-308C-4010-85C3-D16A570BE461Q42229844-C5C47B5D-C687-4E9A-8162-02375ADCF205Q42243024-94215E9A-8ED1-4FB7-8440-51001B79B671Q43470347-D7F879E6-ADB5-460C-981E-76F1E0A956E9Q43535477-ECF67A2B-4CEA-4DB0-947A-D6BFFEC4957CQ43707018-A876EB2A-9162-4475-900E-91CC5DECA715Q43716020-0450F973-C21E-497F-934D-63B305ED7711Q44117626-BE0BA340-4552-4CB6-8FD2-95BE9B1A517DQ44118757-17BBB4A4-7935-4465-8354-9587AF67DF0FQ44527255-FB29C32A-154F-4669-A624-874BA86B20E6Q45434190-B7DAC7C9-FB85-45F3-919D-524E5D947280Q45740735-0AA372B7-3694-4A76-917F-15D2BEA26CB2Q45741782-3566D1CF-AE89-42F7-969B-A32D144E2DFEQ46406633-1007CE1D-C06C-43BA-A02B-7A3280D133D3Q47579694-30B82401-D9D5-4FFB-BAAE-CF331AABE3C4Q48282301-9C0DD7FB-FA9F-4CE0-99A6-75D8B91B667A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
A Ammassari
@ast
A Ammassari
@en
A Ammassari
@es
A Ammassari
@nl
A Ammassari
@sl
type
label
A Ammassari
@ast
A Ammassari
@en
A Ammassari
@es
A Ammassari
@nl
A Ammassari
@sl
prefLabel
A Ammassari
@ast
A Ammassari
@en
A Ammassari
@es
A Ammassari
@nl
A Ammassari
@sl
P106
P1153
7003410809
P31
P496
0000-0002-0284-0340